文献速递胸部肿瘤

周围型Ⅰ期非小细胞肺癌单次碳离子放疗剂量递增临床试验

A Dose Escalation Clinical Trial of Single-Fraction Carbon Ion Radiotherapy for Peripheral Stage I Non-Small Cell Lung Cancer.
PubMed 文献 · J Thorac Oncol · 2016-12-19

这项剂量递增试验纳入218例周围型Ⅰ期非小细胞肺癌患者,单次碳离子放疗总剂量从28 Gy(RBE)递增至50 Gy(RBE)。5年总生存率49.4%,局部控制率72.7%;接受36 Gy(RBE)及以上者局部控制率显著优于低于36 Gy(RBE)者(P=0.0001)。

要点

  • 218例周围型Ⅰ期非小细胞肺癌患者接受单次碳离子放疗,剂量从28 Gy(RBE)递增至50 Gy(RBE)。
  • 5年总生存率49.4%,局部控制率72.7%;接受≥36 Gy(RBE)者局部控制率显著优于<36 Gy(RBE)者(P=0.0001)。
  • 48至50 Gy(RBE)组20例患者5年局部控制率95.0%、总生存率69.2%、无进展生存率60.0%。

核心结论

  • 单次碳离子放疗治疗Ⅰ期非小细胞肺癌的剂量递增研究显示,可获得与既往分次方案相当的优异结果,具有可行性。

研究设计与样本

  • 剂量递增临床试验,2003年4月至2012年2月共治疗218例周围型Ⅰ期非小细胞肺癌患者,总剂量从28 Gy(相对生物效应,RBE)递增至50 Gy(RBE)。
  • 患者中男性157例、女性61例,中位年龄75岁;T1期123例、T2期95例;134例(61.5%)为医学上不可手术。
  • 组织学类型:腺癌146例、鳞状细胞癌68例、大细胞癌3例、黏液表皮样癌1例。

主要发现

  • 中位随访57.8个月(范围1.6-160.7),5年总生存率49.4%,局部控制率72.7%。
  • 接受36 Gy(RBE)及以上与低于36 Gy(RBE)的患者局部控制率差异有统计学意义(P=0.0001,log-rank检验)。
  • 48至50 Gy(RBE)组20例患者(中位随访58.6个月)5年局部控制率95.0%、总生存率69.2%、无进展生存率60.0%。
  • 随剂量递增,局部控制趋于改善。
  • 肺和皮肤不良反应:无3级及以上反应,2级反应低于2%;胸壁疼痛方面,仅1例出现3级晚期毒性。

关键数值与推荐

  • 总剂量从28 Gy(RBE)递增至50 Gy(RBE)。
  • 36 Gy(RBE)及以上与低于36 Gy(RBE)者局部控制率差异有统计学意义(P=0.0001,log-rank检验)。
  • 48至50 Gy(RBE)组20例:5年局部控制率95.0%、总生存率69.2%、无进展生存率60.0%。
  • 不良反应:无3级及以上肺和皮肤反应,2级反应低于2%;胸壁疼痛仅1例3级晚期毒性。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Our objective was to report initial results of a dose escalation trial of single-fraction carbon ion radiotherapy for peripheral stage I NSCLC. METHODS: Between April 2003 and February 2012, a total of 218 patients were treated. The total dose was raised from 28 to 50 Gy (relative biological effectiveness [RBE]). There were 157 male and 61 female patients, with a median age of 75 years. Of the tumors, 123 were stage T1 and 95 were stage T2. A total of 134 patients (61.5%) were medically inoperable. By histological type, there were 146 adenocarcinomas, 68 squamous cell carcinomas, three large cell carcinomas, and one mucoepidermoid carcinoma. RESULTS: The median follow-up was 57.8 months (range 1.6-160.7). The overall survival rate at 5 years was 49.4%. The local control (LC) rate was 72.7%. A statistically significant difference in LC rate (p = 0.0001, log-rank test) was seen between patients receiving 36 Gy (RBE) or more and those receiving less than 36 Gy (RBE). In 20 patients irradiated with 48 to 50 Gy (RBE), the LC rate at 5 years was 95.0%, the overall survival rate was 69.2%, and the progression-free survival rate was 60.0% (median follow-up was 58.6 months). With dose escalation, LC tended to improve. As for adverse lung and skin reactions, there were no patients with grade 3 or higher reactions, and less than 2% had a grade 2 reaction. Regarding chest wall pain, only one patient had grade 3 late toxicity. CONCLUSIONS: We have reported the outcome of a dose escalation study of single-fraction carbon ion radiotherapy for stage I NSCLC, showing the feasibility of obtaining excellent results comparable to those with previous fractionated regimens.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Yamamoto N, Miyamoto T, Nakajima M, et al. A Dose Escalation Clinical Trial of Single-Fraction Carbon Ion Radiotherapy for Peripheral Stage I Non-Small Cell Lung Cancer. J Thorac Oncol. 2016. PMID: 28007628. doi:10.1016/j.jtho.2016.12.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。